Skip to main content

Table 1 Clinical characteristics of the study population

From: Early acquisition of [18F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe—and slightly better!

Characteristics

All scans (n = 27)

[18F]FDOPA uptake

Positive (n = 20)

Negative (n = 7)

Age, years (mean ± SD)

57 ± 13

59 ± 10

50 ± 17

Sex, male/female (%)

37/63

25/75

71/29

Serum calcitonin, pmol/L (median (range))

20.5 (0.29–262)a

62.0 (0.73–262)

5.9 (0.29–61.0)b

Scan indication (in fractions):

Suspected recurrence

13/27

6/20

7/7

Treatment monitoring

10/27

10/20

0/7

Restaging

4/27

4/20

0/7

Acquisition time, min (median (range))

Early

15 (15–19)

15 (15–19)

15 (15–18)

Late

60 (55–69)

60 (55–69)

60 (55–60)

[18F]FDOPA dose, MBq (mean ± SD)

393.8 ± 45.2

394.1 ± 52.6

393.0 ± 10.5

Final diagnosis verification by reference standard (in fractions):

Histology + imaging*

8/27

8/20

0/7

Imaging* + clinical/biochemical data

15/27

8/20

7/7

Histology only

4/27

4/20

0/7

  1. SD standard deviation
  2. *MRI, CT and/or ultrasound
  3. aone missing value (n = 26)
  4. bone missing value (n = 6)